Pfizer Australia and BioNTech announce TGA approval for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine

Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in individuals 5 years and older.

LOXO-435 by Loxo Oncology for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 26, 2023

New method allows non-destructive study of fish teeth

Can we examine the teeth of living fish and other vertebrates in detail, repeatedly over time, without harming them?

December 26, 2024

WHO recommends dropping component of many flu vaccines

The World Health Organization has recommended dropping a component of many flu vaccines because the viruses it protects against appear to have been driven into

September 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.